Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Myriad Genetics (MYGN) Other Non-Current Assets (2016 - 2025)

Myriad Genetics (MYGN) has disclosed Other Non-Current Assets for 13 consecutive years, with $5.6 million as the latest value for Q4 2025.

  • On a quarterly basis, Other Non-Current Assets fell 34.12% to $5.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was $5.6 million, a 34.12% decrease, with the full-year FY2025 number at $5.6 million, down 34.12% from a year prior.
  • Other Non-Current Assets was $5.6 million for Q4 2025 at Myriad Genetics, down from $6.6 million in the prior quarter.
  • In the past five years, Other Non-Current Assets ranged from a high of $22.1 million in Q2 2023 to a low of $3.6 million in Q1 2021.
  • A 5-year average of $10.9 million and a median of $8.4 million in 2021 define the central range for Other Non-Current Assets.
  • Peak YoY movement for Other Non-Current Assets: skyrocketed 566.67% in 2021, then plummeted 60.0% in 2025.
  • Myriad Genetics' Other Non-Current Assets stood at $8.3 million in 2021, then surged by 86.75% to $15.5 million in 2022, then decreased by 0.65% to $15.4 million in 2023, then crashed by 44.81% to $8.5 million in 2024, then plummeted by 34.12% to $5.6 million in 2025.
  • Per Business Quant, the three most recent readings for MYGN's Other Non-Current Assets are $5.6 million (Q4 2025), $6.6 million (Q3 2025), and $7.1 million (Q2 2025).